REVIEW ARTICLE

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways

Holly Green1,2 · Panagiota Tsitsi2 · Ioanna Markaki2 · Dag Aarsland3 · Per Svenningsson1,2

Published online: 28 January 2019 © The Author(s) 2019

Abstract
Cognitive impairment is highly prevalent in patients with Parkinson’s disease (PD) and causes adverse health outcomes. Novel pro-cognitive therapies are needed to address this unmet need. It is now established that there is an increased risk of dementia in patients with type 2 diabetes mellitus (T2DM) and, moreover, T2DM and PD may have common underlying biological mechanisms. As such, T2DM medications are emerging as potential therapies in the context of PD dementia (PDD). In this review, we provide an update on pathophysiological mechanisms underlying cognitive impairments and PDD, focusing on diabetes-related pathways. Finally, we have conducted a review of ongoing clinical trials in PD patients with dementia, highlighting the multiple pharmacological mechanisms that are targeted to achieve cognitive enhancement.

1 Introduction
Parkinson’s disease (PD) has traditionally been considered a movement disorder and its diagnosis relies on the presence of bradykinesia along with rigidity and/or rest tremor [1]. Non-motor symptoms have recently gained attention and quality-of-life studies have shown that PD patients are severely affected by its non-motor aspects. Indeed, increasing recognition has been given to non-motor manifestations; these are incorporated into both the latest Movement Disorder Society (MDS) criteria for PD [1] and particularly into separate MDS criteria for prodromal PD [2]. Among the non-motor symptoms, cognitive impairment and dementia are especially debilitating and they are the strongest component leading to nursing home placement of PD patients.

2 Prevalence of Cognitive Impairments in Parkinson’s Disease (PD)
Cognitive deficits are common in PD, but vary in both quality and severity in different stages of the disease. The spectrum ranges from subjective cognitive decline [3] to mild...
cognitive impairment (MCI) [4] and PD dementia (PDD) [5]. Subjective cognitive decline does not have established criteria, but it is generally defined as a mild impairment noted by the patient, family or caregivers, although performance in formal cognitive testing is within normal range. Little is known about the occurrence of subjective cognitive decline in PD, but it is assumed to precede future progression to MCI and dementia [6, 7]. The main difference between PD–MCI and PDD is the degree to which the cognitive decline affects everyday life functioning, which is minimal in the case of PD–MCI but substantial in PDD [4, 5]. The cognitive decline often hides under more profound motor deficits and only detailed neurocognitive evaluation reveals the grade to which these deficits extend [8]. Among patients with PD, 25–30% have PD–MCI [4, 9], while an additional 30% have a PDD diagnosis [10]. An 8-year cumulative prevalence of 78% for getting a diagnosis of PDD has been reported in a Norwegian cohort [11] and a cumulative incidence of 83% 20 years after initial diagnosis was reported in the Sydney multicentre study of PD [12].

2.1 PD–Mild Cognitive Impairment (MCI)

MCI can affect one or more cognitive domains, and is further subdivided into amnestic MCI, when memory is the predominantly affected domain, and non-amnestic MCI, when domains other than memory are more impaired [13]. Previously, MCI diagnosis was based on subjective complaints from the patient and/or observations from a caregiver or clinician about cognitive difficulties that cannot be explained by age alone and do not interfere with everyday living [14]. However, recently, the MDS Task Force has redefined PD–MCI and established criteria to facilitate the use of a common definition, additionally stating that the deficits should be attributed to PD, excluding other conditions, and that detailed neuropsychological testing should confirm any subjective observation [4].

Older age, longer disease duration, concomitant depression and a higher motor burden are positively correlated with PD–MCI [9]. While MCI most often develops into PDD, amelioration and return to normal cognitive functioning is not uncommon [15]. Non-amnestic, single-domain PD–MCI is the most common according to some studies [9], while others report that multi-domain MCI is the most common [16]. Executive functioning, visuospatial abilities, verbal fluency, memory and language have all been reported to be affected [9, 15]. Accumulating evidence suggest that there are two distinct categories of cognitive dysfunction in PD with different prognoses. The first one is a frontal executive dysfunction that correlates with dopaminergic loss, which is affected by dopaminergic therapy and has a better prognosis. The second type is characterised by visuospatial and semantic fluency deficits attributed to posterior and temporal dysfunction related to cholinergic loss. Prognosis in the latter is more severe, as the patients commonly progress to PDD [17, 18].

2.2 PD with Dementia

Dementia is the most severe cognitive syndrome, defined as acquired objective cognitive impairment affecting multiple cognitive domains that is severe enough to affect activities of daily life (ADL) [19]. PDD affects multiple cognitive domains, including attention, memory, executive and/or visuospatial ability [5]. In addition to this, PDD is characterised by neuropsychiatric features such as hallucinations and delusions, apathy, depression and anxiety [5]. PDD shares a lot of similarities with dementia with Lewy bodies (DLB), the latter presenting in close chronological proximity to the initiation of motor symptoms as opposed to PDD where parkinsonian semiology must precede cognitive deficits by at least 1 year [20]. Progression from PD or PD–MCI to PDD cannot be predicted but several risk factors have been identified [15]. These includes PD diagnosis at an older age, akinetic–rigid motor subtype, psychiatric manifestations, loss of postural control, dysautonomia, and rapid eye movement (REM) behaviour disorder (RBD) [5, 21].

Multiple mechanisms seem to be involved in the genesis of cognitive decline in PD. Limbic and cortical Lewy body pathology, as well as amyloid plaque and tau pathologies, are the most common contributors to PDD [22]. Additionally, the role of vascular disease [23] and neuroinflammation [24] has been emphasised. In order to explain the clinical heterogeneity between PDD patients, other mechanisms have also been examined such as the role of synaptic proteins [25], neurotransmitters [26] and genetic factors [26, 27].

Studies on glucosylceramidase beta (GBA) mutations have indeed highlighted a high risk for carriers to develop PD with a more rapid cognitive decline [27]. Moreover, several autosomal dominant α-synuclein mutations cause PD with a worse cognitive prognosis [28]. On the other hand, leucine-rich repeat kinase 2 (LRRK2) and parkin mutations have been described to lead to a milder PD phenotype with less cognitive decline [15, 28]. The role of polymorphisms in genes such as microtubule-associated protein tau (MAPT), apolipoprotein E (APOE) and catechol-O-methyltransferase (COMT) on cognitive outcomes has been examined, but results are not yet conclusive [15, 18, 28].

With regards to wet biomarkers, reduced cerebrospinal fluid (CSF) amyloid β 1–42 (Aβ1–42) concentration is consistently associated with cognitive impairment and predicts dementia development [29], while high levels of neurofilament (NFL) [30], inflammatory glycoprotein YKL-40 [31] and neurogranin [25] have been associated with cognitive
decline in PD. Furthermore, it has been reported that PDD patients have increased CSF levels of total and phosphorylated tau and α-synuclein; however, there are still inconsistencies between different studies [32].

In the field of neuroimaging, several modalities have been used to investigate PD–MCI and PDD. Magnetic resonance imaging (MRI) with various structural and functional techniques along with positron emission tomography (PET) and single-photon emission computerised tomography (SPECT) of various tracers (glucose metabolism, cholinergic, amyloid and tau PET) have mainly been used [15, 33, 34]. Structural MRI studies have shown that there is an early cortical thinning in PDD [35] and PD–MCI patients have parietal cortical thinning as well as lower left orbitofrontal cortex grey matter volume as compared to non-demented PD patients [36]. It has also been reported that PD patients have reduced glucose metabolism compared to controls in a range of regions including the parietal and prefrontal cortices [37–39]. Moreover, PD patients with cognitive impairment have reduced metabolism in the temporal, parietal and premotor cortices as compared to PD patients without cognitive decline [38, 39]. Additionally, electroencephalography and magnetoencephalography studies have shown promising results in terms of predicting cognitive deterioration in PD [40].

3 Role of Diabetes-Related Pathways and Antidiabetic Drugs in PD Dementia (PDD)

Various mechanisms are involved in the underlying pathology of cognitive decline in PD. These include limbic and cortical Lewy body pathology, amyloid plaque and tau pathology, neuroinflammation, synaptic plasticity dysregulation, neurotransmitter alterations as well as genetic factors [15, 18, 22–26, 28]. The complex roles of these in the underlying pathology of PDD has been previously reviewed in depth [41, 42]. There is accumulating evidence that diabetes-related pathways are involved in cognitive decline in PD and here we focus on these mechanisms.

3.1 PD and Diabetes

Although PD and diabetes are clinically different, an association between the two disorders was described in the 1960s, with the assessment of glucose tolerance in PD patients [43]. It was later suggested that alterations in similar pathways and common underlying mechanisms exist between the two disorders [44, 45].

Several epidemiological studies have demonstrated an association between type 2 diabetes mellitus (T2DM) and an increased risk of developing PD [46–50]. More specifically, a large proportion of PD and PDD patients have impaired insulin signalling and insulin resistance [44, 51]. A prospective epidemiological study in a Finnish population found an association between T2DM and the risk of developing PD [46] and, furthermore, T2DM has been associated with a younger onset of PD and more severe symptoms [47, 48]. However, in contrast, some studies did not find diabetes to be a risk factor for PD and even reported a lower prevalence of diabetes in PD patients than in controls [45, 52–54]. Despite these conflicting reports, it has been suggested that the diseases may have common underlying biological mechanisms [44, 45]. Mitochondrial dysfunction, autophagy, inflammation and impaired insulin signalling deficits and resistance have all been associated with PD, PDD and diabetes [44]. In addition to shared biological pathways, whole-genome transcriptome profiling of the substantia nigra of PD patients has provided evidence of genetic links between PD and diabetes [55]. It was found that 892 dysregulated priority genes were altered, and various ‘hub’ genes with multiple interactions with other genes were identified, including those encoding glycogen synthase kinase-3β (GSK-3β) and insulin-like growth factor-1 (IGF-1) receptor (IGF-1R). Furthermore, diabetes was among the top three diseases showing the strongest probable relationship to the top upregulated priority genes [55]. Network-based approaches provide further evidence for a molecular link between diabetes and PD [56]. Interactome mapping revealed more than 400 genes linking both T2DM and PD and identified insulin receptor and lipid signalling, activation of the immune response, mitogen-activated protein (MAP) kinase (MAPK) cascade and protein serine–threonine kinase activity as convergent pathways [57].

3.2 PD, Diabetes and Dementia

The link between diabetes and PDD was noted back in 1992 when Sandyk and Awerbuch [58] reported an association between the two conditions in a small study of 12 PD patients. In their study, all five PD patients with diabetes also had dementia while the seven diabetes-free PD patients did not exhibit dementia at the time [58]. Since then the field investigating diabetes and PDD has grown. Bosco et al. [51] reported that PD patients with dementia are two times more likely to be insulin resistant than PD patients without dementia [51].

3.3 Diabetes and Dementia

In addition to lifestyle factors, such as obesity and physical inactivity, increased longevity and population aging are crucial factors contributing to the increasing prevalence.
of T2DM worldwide [59]. Similar trends are observed in the prevalence of dementia, resulting in co-occurrence of the two diseases [60]. It is now established that there is an increased risk of dementia in patients with T2DM [61, 62]. Diabetes is also linked to less severe forms of cognitive dysfunction, including MCI [63, 64] and subtle cognitive changes reported under the term diabetes-associated cognitive decrements [65]. Diabetes-associated cognitive decrements in adults with T2DM are commonly subtle changes in cognitive function that may be bothersome, but do not affect ADL [65]. These cognitive decrements affect one or several domains, including processing speed, executive function, visual and verbal memory, as well as motor function [66]. It has been suggested that diabetes-associated cognitive decline develops during the pre-diabetic stages, and advances very slowly, over many years [67]. Cognitive decrements do not represent a pre-dementia stage in patients younger than 60 years, whereas older patients may progress to MCI and dementia [65].

An increasing body of evidence suggests that neurodegenerative and vascular dementias share some common underlying pathologies, such as insulin dysregulation, that act both through disease-specific and general mechanisms [68]. In a meta-analysis of 14 studies including over 2 million people, T2DM was associated with a 60% increased risk for dementia of all types, and for vascular dementia the additional risk was 19% higher in women than in men [69]. Radiological signs of vascular brain injury such as lacunes and white matter hyperintensities are common findings in patients with T2DM [70]; however, neuropathologic studies do not confirm increased occurrence of large artery infarcts or microinfarcts in these patients [71]. Also, although the risk for Alzheimer’s dementia is increased in patients with T2DM, neither Alzheimer’s pathology in the brain [72] nor in vivo biomarkers of amyloid β deposition and tau pathology [73, 74] are more common in patients with diabetes than in non-diabetic individuals. These findings may indicate that T2DM accelerates neurodegeneration by other, non-Alzheimer’s-specific mechanisms, which may also contribute in other dementia syndromes, such as PDD. One such mechanism is insulin resistance, which appears in T2DM and neurodegenerative dementias including PD [75, 76]. Insulin resistance is a core sign of T2DM that, besides hyperglycaemia, also contributes in oxidative stress, inflammation, atherosclerosis and hyperlipidaemia. Brain insulin resistance has been defined as the failure of nerve cells to respond normally to insulin, with subsequent disturbances in synaptic, metabolic and immune response functions [77]. Systemic insulin resistance and T2DM are associated with brain insulin resistance and with neurodegeneration; however, it is unclear whether the inter-relation of these conditions depends on mechanistic links or co-occurrence of processes of aging [75].

### 3.4 Insulin, Insulin-Like Growth Factor (IGF)-1 and Insulin Resistance in Relation to PD

Insulin is thought to have neuroprotective functions in the central nervous system (CNS) [78]. Animal studies have shown that downregulating insulin receptor expression in the rat hippocampus impairs hippocampal plasticity, spatial learning and long-term potentiation [79]. Conversely, insulin treatment has been shown to improve memory and cognition in rats [80] and promote protective effects in rat models of PD [81]. IGF-1 is a neuronal survival factor and is closely related to insulin (Fig. 1). IGF-1 can bind to both the insulin receptor and IGF-1R with similar outcomes, and animal studies have demonstrated that IGF-1 can exert a neuroprotective effect on neurons in in vitro and in vivo models of PD and reduce α-synuclein aggregation [82–84]. IGF-1 levels are increased in the serum and CSF of PD patients [85–87], possibly as an endogenous neuroprotective response. Lower serum IGF-1 levels in PD patients have been associated with poor executive function [88] and found to predict poor verbal memory performance [89].

Peripheral insulin and IGF-1 can cross the blood–brain barrier (BBB) and animal studies have shown that they are also produced in regions of the CNS associated with cognition and dementia, including the hippocampus, cortex and olfactory bulb [76, 90–92]. The insulin receptor is widely expressed in the brain—in the olfactory bulb, cerebral cortex, hippocampus, hypothalamus, amygdala [93] and substantia nigra [76, 94]. It is more concentrated in neurons than in glial cells and is present in post-synaptic neuron terminals [93]. To induce signalling, IGF-1 or insulin bind to the insulin receptor, causing autophosphorylation of the intracellular unit. This causes a signalling cascade resulting in the activation of either the mammalian MAPK/extracellular signal-regulated kinases (ERK) signalling pathway, resulting in cell growth, or the phosphoinositide 3-kinase (PI3 K)/protein kinase B (AKT) signalling pathway for metabolic functions, resulting in cell proliferation and survival, and the synthesis of lipids and proteins [95] (Fig. 1). The activation of these pathways can modulate multiple downstream targets [76, 96] (Fig. 1). This results in the modulation of pathways in PD and PDD, such as apoptosis (mammalian target of rapamycin [mTOR], GSK-3β and forkhead box O [FoxO]), autophagy (mTOR), inflammation (GSK-3β and nuclear factor-κB [NFκB]) and synaptic plasticity (GSK-3β), and cyclic adenosine monophosphate [cAMP] response element-binding protein [CREB]). GSK-3β has been widely researched in neurodegenerative disorders, inflammation and cognition as well as diabetes, playing a role in each. Of note, α-synuclein, a key player in both PD and PDD can activate GSK-3β directly and indirectly by inhibiting insulin receptor substrate 1, thereby altering insulin signalling [76, 97–99].
Dysfunctional insulin signalling due to insulin resistance, diabetes or excessive inflammation [100] may result in activated GSK-3β and NFκB and inactivated mTOR and CREB signalling, among others, resulting in altered autophagy, cell proliferation and increased inflammation (Fig. 1). Indeed, loss of insulin sensitivity centrally in animal models of Alzheimer’s disease (AD) has resulted in increased formation of AD-related pathology [101]. Willette et al. [102] have shown that insulin resistance is associated with higher frontal and temporal amyloid levels in normoglycaemic participants. In contrast, activation of the insulin degrading enzyme (IDE) results in degradation of amyloid β under

---

**Fig. 1** Potential neuroprotective mechanisms of antidiabetic drugs in the context of Parkinson’s disease dementia. ChEs block ACh degradation by ChE allowing ACh to bind to either the mAChR or nicotinic receptors resulting in MAP kinase signalling. IGF-1 or insulin bind to the IR activating MAP kinase signalling, promoting cell growth and synaptic plasticity via BDNF, or the PI3 K/AKT signalling pathway, resulting in cell proliferation and survival via modulating multiple downstream targets including mTOR, GSK-3β, FoxO and NFκB. DPP-IV inhibitors block the degradation of GLP-1 by DDP-IV, promoting signalling, while GLP-1 analogues directly promote GLP-1R signalling, which increases cAMP activating of the aforementioned signalling pathways and also activates the PKA signalling pathway resulting in the activation of CREB and resultant gene transcription. Proinflammatory cytokines, which are elevated in Parkinson’s disease, such as TNFα and IL-1 promote pro-inflammatory cytokine release via NFκB signalling and can also inhibit insulin and IGF-1 signalling, resulting in the disruption of MAP kinase and PI3 K signalling. In contrast to this, glitazones can activate PPARγ, resulting in gene transcription of neuroprotective mediators. PGC-1α can bind to various transcription factors including PPARγ and exerts a neuroprotective effect. The insulin degrading enzyme can target α-syn, binding to α-syn oligomers inhibiting the formation of fibrils. α-syn alpha-synuclein, ACh acetylcholine, AKT protein kinase B, ChE cholinesterase, ChI cholinesterase inhibitor, BDNF brain-derived neurotrophic factor, cAMP cyclic adenosine monophosphate, CREB cyclic adenosine monophosphate response element-binding protein, DPP-IV dipeptidyl peptidase IV, FoxO forkhead box O, GLP-1 glucagon-like peptide-1, GLP1R glucagon-like peptide-1 receptor, GSK3β glycogen synthase kinase-3β, IDE insulin degrading enzyme, IGF-1 insulin growth factor-1, IL-1 interleukin-1, IR insulin receptor, mAChR muscarinic acetylcholine receptors, MAP mitogen-activated protein, mTOR mammalian target of rapamycin, NFκB nuclear factor-κB, PI3 K phosphatidylinositol 3 kinase pathway, PGC-1α PPARγ coactivator 1α, PKA protein kinase A, PPARγ proliferator-activated receptor-γ, TNFα tumour necrosis factor-α

| Drug | Action |
|------|--------|
| Saxaliptin | Anti-inflammatory mediator |
| Sitagliptin | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |
| Lixisenatide | GLP-1 ana logues |
| Liraglutide | GLP-1 ana logues |

**Cell proliferation**

**Synaptic plasticity**
physiological conditions [103], which is of particular interest due to the fact that amyloid β levels have been associated with memory decline and cognitive impairment in PD [104–106]. Furthermore, upon activation, IDE can target α-synuclein, the main component of Lewy bodies, binding to α-synuclein oligomers, inhibiting the formation of fibrils [107].

In addition to the aforementioned pathways, it has been suggested that low concentrations of insulin together with reduced receptor levels, and thus reduced signalling, would result in decreased acetylcholine [108]. Reductions in cortical choline acetyltransferase correlate with cognitive impairment in PD [109] and there is widespread loss of cortical acetylcholine in PDD [110, 111]. Taken together, it is evident that insulin plays a role in many of the proposed pathological mechanisms in PDD, including autophagy, inflammation, apoptosis, synaptic plasticity and neurotransmitter alteration.

3.5 Glucagon-Like Peptide-1 (GLP-1), GLP-1 Analogues and Dipeptidyl Peptidase IV (DPP-IV) Inhibitors

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that maintains glucose homeostasis and facilitates insulin signalling by stimulating insulin secretion and biosynthesis as well as inhibiting glucagon secretion [112]. GLP-1 is primarily produced in the small intestine and is also thought to be produced in the CNS in the lower brainstem and in the axons of the hypothalamic nuclei as well as by microglia [113, 114]. GLP-1 binds to the G-protein coupled receptor (GPCR) GLP-1R, which has been shown to be expressed widely in the brain [115, 116]. In addition to its role in regulating glucose homeostasis, GLP-1 is also involved in cell proliferation, neuronal growth, inhibiting apoptosis and reducing oxidative stress in the CNS [117]. Interestingly, Kappe and colleagues [113] have demonstrated that GLP-1 expression is decreased in response to a lipopolysaccharide (LPS)-mediated inflammation challenge in vitro. The structure of GLP-1R in complex with a Gs protein has recently been revealed [118]. In general, this study has facilitated the integration of a large body of biochemical and biophysical data towards understanding the activation of GPCRs through peptide binding. GLP-1 binding to GLP-1R increases cAMP, and, similarly to IGF-1 and insulin signalling, activates the PI3 K signalling pathway resulting in the activation of AKT signalling pathways [119] (Fig. 1). The dipeptidyl peptidase IV (DPP-IV) enzyme degrades GLP-1, thus inhibiting downstream signalling. As such, GLP-1 analogues and DPP-IV inhibitors have been developed as T2DM drugs, and have been found to have protective functions in PD animal models, protecting against cell death and having anti-inflammatory effects [112, 119]. Indeed, it has been suggested that the protective effect of antidiabetic drugs observed in PD may partly be mediated by their anti-inflammatory effects [44]. GLP-1 analogues and DPP-IV inhibitors can cross the BBB, and affect neuroinflammation, mitochondrial function and cellular proliferation, among others. Moreover, because GLP-1R stimulation activates similar signalling pathways that are ‘de-activated’ as a consequence of insulin resistance, it has been suggested that the ability to restore brain insulin sensitivity also underlies the neuroprotective effect of GLP-1 analogues. Using a population-based register study, we have recently found that patients with T2DM treated with GLP-1R agonists or DPP-4 inhibitors have a lower incidence of future PD [120]. GLP-1 analogues, such as exenatide, liraglutide and lixisenatide, and DPP-IV inhibitors, including saxagliptin, vildagliptin and sitagliptin, have also been found to have neuroprotective effects in vitro and in vivo animal models of both PD and AD. This has been comprehensively reviewed by Athauda and Foltynie [76, 112, 117] and by Hölscher [121, 122]. Of particular note here is that GLP-1R activation using exendin-4 has been shown to promote acetylcholine production in NSC-19 neuroblastoma cells in vitro [123], which has specific relevance in relation to the loss of cortical acetylcholine in PDD [110, 111]. Moreover, exendin-4 stimulates subventricular zone neurogenesis in the rodent brain and induces behavioural and histological recovery in an animal model of Parkinsonism [124].

3.6 Glitazones

Insulin-sensitizing thiazolidinediones (TZDs) are another group of antidiabetic drugs that have been investigated in relation to PD. TZDs increase insulin sensitivity by targeting peroxisome proliferator-activated receptor (PPAR)-γ. PPARs have been identified centrally in non-human primates in regions including the ventral tegmental nucleus, putamen and substantia nigra [125]. Furthermore, PPARs are expressed in adult human brain in an isotype- and cell-specific manner; PPARγ is found in neurons and astrocytes but not in microglia in postmortem superior frontal gyrus [126]. However, PPARγ is expressed in mouse microglia after an LPS challenge [126]. PPARs are ligand-dependent transcription factors and PPARγ agonists inhibit proinflammatory cytokine production [127, 128]. As neuroinflammation plays a role in many neurodegenerative disorders, investigation of PPAR agonists has gained momentum. Indeed, pioglitazone has been found to have protective properties in rodent models of PD, reducing mediators of oxidative stress including nitric oxides and mitochondrial outer membrane protein [129], decreasing glial activation and NFκB signalling, and protecting dopaminergic neurons [130, 131]. Furthermore, pioglitazone had neuroprotective effects in experimental parkinsonism in rhesus monkeys [132], and in a retrospective register study, Brauer and colleagues [133].
reported that diabetic patients also being treated with glitazones had a lower incidence of PD. However, a phase II multicentre double-blind randomized trial of pioglitazone with PD patients did not find protective effects of the drug (ClinicalTrials.gov identifier NCT01280123). This could be due to the relatively short follow-up time (44 weeks) of early diagnosed PD patients, which is not consistent with large changes in cognitive scores even in the natural course of the disease. In early PD patients the sensitivity to evaluate early and mild cognitive impairment is low [134]. It could also be attributed to inefficient penetration of the drug in the human brain, contrary to previous positive results in animal models [135]. Despite this, more recently pioglitazone was shown to protect against the risk of dementia in patients with T2DM [136]. Recently, attention has been drawn to the PPARγ coactivator 1α (PGC-1α). PGC-1α is involved in gluconeogenesis and mitochondrial biogenesis and, interestingly, GLP-1 has been found to increase PGC-1α in rat pancreatic β cell lines [137]. Polymorphisms in PGC-1α have been associated with the risk and age of onset of PD [138], while overexpression of PGC-1α has a neuroprotective effect on dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD, while also protecting against α-synuclein-induced dopaminergic cell death [139, 140].

4 Current Treatment of PDD

Cholinergic dysfunction is one of the pathophysiological mechanisms that play a critical role in cognitive impairment in PD, and is targeted by cholinesterase inhibitors (ChIIs) for the treatment of Lewy body disorders (PD, PD–MCI, PDD and DLB) [17, 141–148]. In a large meta-analysis assessing the efficacy and safety of 17 clinical trials for PDD and DLB, rivastigmine and donepezil were reported to have a beneficial effect on cognitive function, behavioural disturbances, ADL and global function. Furthermore, there were no detrimental effects on motor function compared with placebo [149]. There was, however, a higher rate of all-cause discontinuation of treatment and discontinuation due to adverse events (AEs) in the ChIIs group than in controls. Nausea and tremor were common in all ChIIs and vomiting and dizziness were more often associated with rivastigmine. It is concluded that ChIIs are beneficial in the treatment of Lewy body disorders, including PDD. An experimental medicine study [150] with a rivastigmine patch used functional MRI evaluations to assess pre-cognitive effectiveness. Despite a rather small number of participants, the study results implicate the use of rivastigmine with frontal function amelioration. Rivastigmine has also been tested against MCI in PD patients and had some beneficial actions, but failed to meet its primary outcome on global clinical improvement [151]. Apart from ChIs, there have also been studies that evaluated the effect of N-methyl-D-aspartate (NMDA) receptor antagonists in PDD. Memantine affects the glutamatergic neuronal transmission and prevents toxicity from high concentrations of glutamate. Based on previous findings of altered glutamatergic markers in DLB, scientists have conducted studies on the effect of memantine on DLB and PDD [152–154]. The studies were multicentre and double-blind and medication was titrated to 20 mg. Pooled data presented in a meta-analysis confirmed a significant effect of memantine on the Clinician’s Global Impression of Change scale and good safety outcomes. However, no effect on cognitive function, behavioural symptoms or ADL was reported [155].

5 Recent and Ongoing Drug Studies Against PD-MCI and PDD

The electronic databases ClinicalTrials.gov and the European Union Clinical Trials Register were searched using the terms “Parkinson’s disease” and “dementia or cognitive impairment”. Cross-references from the identified articles were also scrutinised for relevant studies. Litvan and colleagues [156] recently reviewed previous clinical trials in PD-MCI. As well as critically reviewing previous trials, they also highlight important factors to be considered for future PD-MCI trials including clarity on which cognitive syndrome investigators are addressing (for trial design), improved outcome measure choice and meaningful biomarkers [156]. As such, in this section we discuss ongoing trials.

5.1 Drugs Primarily Acting on Neurotransmitter Mechanisms

5.1.1 Glutamatergic Mechanisms

Sarcosine is a glycine transporter I inhibitor that blocks glycine uptake and enforces the function of the NMDA receptor. Glycine works as a potentiator via the NR1 subunit of the NMDA receptors. A placebo-controlled, double-blind study has shown that sarcosine has a positive effect on neuropsychiatric symptoms of PDD (NCT01785628) [157]. Patients received placebo or 2 mg of sarcosine daily for 8 weeks. Efficacy regarding neuropsychiatric symptoms and safety regarding AEs were the primary endpoints and the Unified Parkinson’s Disease Rating Scale (UPDRS) and cognitive assessment were the secondary endpoints. Temporary dizziness was the only AE reported in the sarcosine group and temporary neuropsychiatric amelioration was achieved in the treatment group, but no differences in cognition or motor function were reported. The researchers indicate a possible

△ Adis
tolerance to sarcosine after a relatively short period of treatment and a need for larger studies.

Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic that has been shown to reduce glutamatergic hyperactivity and excitotoxicity and exert neuroprotective properties in preclinical PD models [158–160]. A phase II trial of ceftriaxone in PDD in which efficacy and safety are going to be investigated is ongoing in Taiwan (NCT03413384; Table 1). Patients will receive ceftriaxone 1 g or placebo on days 1, 3 and 5 per cycle on a 2-weekly cycle.

A phase I dose-finding clinical trial of NYX-458, a modulator of NMRA receptors, has been initiated. The aim is to optimize conditions for a phase II trial in PDD. A press release has reported that a preclinical study on a non-human primate model of PD-related cognitive impairment showed that NYX-458 significantly increased sustained attention, improved cognitive flexibility and enhanced working memory. These effects were present as early as 2 h following a single oral dose and remained 3 weeks post-dosing. NYX-458 resulted in complete reversal of cognitive impairment and performance back to baseline levels. No issues of tolerability were observed.

5.1.3 Monoaminergic Mechanisms

Atomoxetine is a selective norepinephrine reuptake inhibitor that affects dopaminergic and noradrenergic transmission in frontal areas of the brain and is approved for the treatment of attention deficit disorder. It has also been investigated with positive results in non-demented PD patients with executive dysfunction in an 8-week, pilot, open-label, flexible-dose study [164]. The study reported improved executive dysfunction and only mild to moderate AEs, including sleep and gastrointestinal disturbances and hypomania. Another randomised, double-blind, placebo-controlled trial (NCT01738191; Table 1) on the potential benefit of atomoxetine on PD-MCI has just been completed, but the results are yet to be published.

Serotonin receptors have received increased attention in the context of non-motor symptoms in neurodegenerative disorders and the use of pimavanserin, a serotonin 5-HT2A antagonist, has already been approved for PD psychosis [165]. Furthermore, 5-HT6 and 5-HT7 receptor antagonists have been shown to produce promnesic and anti-amnesic effects in preclinical models, as well as in humans with schizophrenia, PD or AD [166]; however, early results from phase III studies in AD have failed to demonstrate significant impact on cognition [167]. SYNAPSE is a proof-of-concept study that assessed the safety, tolerability and efficacy of a dual 5-HT6/5-HT2A antagonist (SYN120) in patients with PDD and ongoing treatment with ChE (NCT02258152; Table 1). Recruitment was completed in October 2017 but no results are available yet. Nelotanserin is a selective 5-HT2A inverse agonist that can be administered orally and has been tested on sleep-maintenance insomnias [168]. There is an ongoing clinical trial on the effect of nelotanserin against RBD in patients with PDD and DLB (NCT02708186; Table 1). It is investigating the safety and efficacy of nelotanserin, based on motor scales and clinical evaluation of the REM sleep behaviours. Additionally, another study (NCT02871427; Table 1) is evaluating the long-term safety, tolerability and effectiveness of nelotanserin in DLB and PDD, targeting mainly psychiatric semiology and RBD.

The potentially beneficial role of intepirdine (RVT-101) in cognition has already been highlighted in AD [169]. It is a 5-HT6 antagonist that has been implicated as playing an important role in multiple pathways. Intepirdine has also been investigated in DLB and there has been a study on AD, DLB and PDD (NCT02910102; Table 1) that assessed its effect on gait and balance. To date, no results have been published.

LY3154207 is an orally administered enhancer of dopamine D1 receptors that is under investigation in a multicentre, phase II trial in the USA for patients with PDD (NCT03305809; Table 1). In addition, the pharmacokinetic properties of LY3154207 are going to be assessed in the Multiple-Arising Dose, Safety, Tolerability, and Pharmacokinetic Study in healthy subjects and PD patients (NCT02562768; Table 1).
### Table 1: Clinical trials investigating novel treatments for Parkinson’s disease dementia

| ClinicalTrials.gov/EudraCT identifier | Study design | Estimated enrolment (n) | Agent | Mechanism of action | Comparison | Relevant outcome measures |
|---------------------------------------|--------------|-------------------------|-------|---------------------|------------|--------------------------|
| NCT02415062                           | R, OL prospective, paralleled study | 150 | Donepezil | ChI | Donepezil 25 mg (high dose) vs. donepezil 10 mg (standard dose) | General cognitive function assessed with Korean MMSE-2. Timeframe: change from baseline to week 24 |
| NCT03413384                           | R, DB, PC, phase II study | 106 | Ceftriaxone | Cephalosporin antibiotic | Ceftriaxone vs. placebo | Assessment of memory, orientation, language, and praxis measured with ADAS-Cog. Timeframe: change from baseline to weeks 17 and 33 |
| 2017-004335-36                        | R, DB, PC, phase II study | 120 | ANAVEX2-73 | Sigma-1 receptor agonist | ANAVEX2-73 vs. placebo | Continuity of attention measured by CDR computerised assessment system continuity of attention test |
| NCT01738191                           | R, DB, PC | 30 | Atomoxetine | Norepinephrine reuptake inhibitor | Atomoxetine vs. placebo | Assessment of 7 atomoxetine-sensitive neuropsychological measures of attention, set-shifting, information processing speed and working memory. Timeframe: change from baseline to 10 weeks |
| NCT02258152                           | R, DB, PC, POC | 82 | SYN120 | Dual 5-HT₆/5-HT₂A antagonist | SYN120 vs. placebo | Assessment of CDR cognition battery continuity of attention. Timeframe: baseline to week 16 |
| NCT02708186                           | R, DB, PC | 20 | Nelotanserin | Selective 5-HT₂A inverse agonist | Nelotanserin vs. placebo | Assessment of the frequency of REM sleep behaviours. Timeframe: baseline to day 28 |
| NCT02871427                           | MC, OL long-term study | 80 | Nelotanserin | Selective 5-HT₂A inverse agonist | Nelotanserin 20, 40, 60 or 80 mg | Assessment of the frequency and severity of hallucinations, and REM sleep behaviours. Timeframe: 24 weeks |
| NCT02910102                           | R, DB, PC, phase II crossover study | 38 | Intepirdine | Selective 5-HT₆ receptor antagonist | Intepirdine vs. placebo | Quantitative gait measurements assessed by computerized gait assessment tools. Timeframe: baseline to week 12 |
| NCT03035809                           | R, DB, PC, phase II study | 340 | LY3154207 | Dopamine receptor D₄ enhancer | LY3154207 vs. placebo | Assessment of Continuity of Attention measured by CDR computerised cognition battery continuity of attention composite score. Timeframe: baseline to week 12 |
| ClinicalTrials.gov/EudraCT identifier | Study design | Estimated enrolment (n) | Agent | Mechanism of action | Comparison | Relevant outcome measures |
|--------------------------------------|--------------|-------------------------|-------|---------------------|------------|--------------------------|
| NCT0256278                           | R, DB, PC, multiple-ascending dose study | 80     | LY3154207          | Dopamine receptor D<sub>1</sub> enhancer | LY3154207 vs. placebo | Assessment of serious adverse events and pharmacokinetic properties. Timeframe: baseline through day 15 |
| NCT01256905                          | OL           | 20                     | Armodafinil | Dopamine reuptake inhibitor | Armodafinil | Evaluation of striatal-thalamo-cortical network disturbances assessed with EEG. Timeframe: 2 h |
| 2017-001673-17                        | R, DB, PC, MC, phase IIa study | 40     | IRL752             | 5-HT<sub>7</sub> and α-adrenergic receptor antagonist | IRL752 vs. placebo | Safety, tolerability and efficacy on motor and non-motor symptoms including cognitive function measured with CANTAB and EEG pattern changes. Timeframe: baseline to day 28 |
| 2010-024424-26                        | Prospective, MC, R, DB, PC, parallel group, phase II study | 45     | Masitinib          | Non-selective tyrosine kinase receptor inhibitor | Masitinib vs. placebo | Assessment of cognition with ADCS instruments. Timeframe: baseline to week 48 |
| NCT02954978                           | R, DB, PC    | 75                     | Nilotinib          | C-Abelson tyrosine kinase inhibitor | Nilotinib 300 mg vs. nilotinib 150 mg vs. placebo | Assessment of adverse events and pharmacokinetic properties and measurement of biomarker of dopamine metabolism in cerebrospinal fluid. Timeframe: baseline to 12 months |
| NCT02914366                           | R, DB, PC    | 75                     | Ambroxol           | Chaperone, glucocerebrosidase stabiliser | Ambroxol 1050 mg vs. ambroxol 525 mg vs. placebo | Assessment of cognition with ADAS-Cog and ADCS–Clinician's Global Impression of Change. Timeframe: baseline to week 26 and week 52 |
| NCT02906020                           | R, DB, PC    | 243                    | GZ/SAR402671 (ibiglustat) | Glucosylceramide synthase inhibitor | GZ/SAR402671 vs. placebo | Assessment of MDS-UPDRS and Parkinson's disease Cognitive Rating Scale. Timeframe: baseline to week 8 and at week 52 |
| NCT03456687                           | OL           | 20                     | Exenatide          | GLP-1 receptor agonist | Exenatide | MRI and fMRI-based markers of free-water accumulation in substantia nigra, blood oxygen level-dependent signal in the posterior putamen, in M1 and in the supplementary motor areas. Timeframe: baseline to 1 year |
Armodafinil is a dopamine reuptake inhibitor that acts as a wake-promoting agent, and has been shown to have positive effects on cognition, daytime sleepiness and visual hallucinations in patients with narcolepsy [170]. It has also been evaluated in a small, open-label, single-dose study in nine patients with DLB and PDD with positive results on attention and global mental status [171]. Another pilot study of 20 patients with PDD and DLB reported improvement in hypersomnia and wakefulness and reasonable safety and tolerability of armodafinil during 12 weeks of treatment [172]. In the next phase, a larger, open-label study (NCT01256905; Table 1) will evaluate the effect of armodafinil on attention modulation in PDD and DLB patients.

IRL752 belongs to a new class of CNS-active agents called psychomotor stabilisers. Such compounds modify psychomotor activity depending on the initial level of activity. In preclinical models, IRL752 potentiates cortical transmission of dopamine, noradrenaline and acetylcholine and has procognitive effects. This provided the rationale for developing IRL752 as a potential therapy against PDD. A multicentre phase IIa study evaluating the safety and tolerability of IRL752 in PDD patients is currently ongoing in Sweden and Finland (EudraCT: 2017-001673-17; Table 1). A press release has reported positive data on cognition and apathy, but no results have been published.

5.2 Drugs Primarily Acting on Intracellular Enzymes

5.2.1 Protein Kinase Inhibitors

Masitinib is a non-selective tyrosine kinase receptor (TKR) inhibitor currently being tested against cognitive impairment in PD in a phase II study assessing safety and efficacy (EudraCT: 2010-024424-26; Table 1). The primary target of masitinib is the TKR c-Kit, but it also exerts weak inhibitory activity in fibroblast growth factor receptor 3, lymphocyte-specific kinase (Lck), Lck/Yes-related protein, focal adhesion kinase and the Fyn TKR. It also targets platelet-derived growth factor receptor and is currently being used in the treatment of mast cell (MC) tumours in dogs, and in oncology for the treatment of unresectable or metastatic gastrointestinal stromal tumours [173]. Clinical use of masitinib in non-oncological applications seems reasonable, based on the involvement of c-Kit receptors in MC-mediated inflammatory pathogenesis.

Another biochemical pathway of increasing interest in PD is that of the C-Abelson (C-Abl) tyrosine kinase enzyme. C-Abl is phosphorylated and activated upon mitochondrial dysfunction, resulting in increased oxidative stress and dopamine neuron degeneration supposedly through parkin inactivation, α-synuclein aggregation and impaired autophagy of toxic elements [174]. The C-Abl inhibitor nilotinib, which is used in much higher doses in leukaemia treatment, has
been investigated in a small, open-label, proof-of-concept trial on 12 patients with advanced PD or DLB with good results on safety and tolerability during 24 weeks of treatment; however, one patient had a myocardial infarction and two had a corrected QT (QTC) interval prolongation on electrocardiogram [175]. Secondary objectives included the determination of the ability of nilotinib to cross the BBB, and to determine target engagement through measurements of phosphorylation of Abl in CSF. The study had very high coverage by the media when initially presented and a great impact on decision-making among patients and physicians. This led to a great escalation of off-label prescription of nilotinib, which in turn led to call for further, larger studies to include a control arm [176]. A larger phase II study is now underway (NCT02954978; Table 1) and is estimated to be completed by 2020.

5.2.2 Glucocerebrosidase Targeting

There are currently two clinical trials investigating drugs targeting glucocerebrosidase (GCase). Targeting the function of the GBA-encoded enzyme, GCase is a relatively new therapeutic approach in PDD. NCT02914366 is a currently recruiting study on the safety, tolerability and efficacy of ambroxol, a GCase chaperone, in PDD patients (Table 1). It is thought that as ambroxol will increase lysosomal function and has been shown to improve GCase functions it may reduce α-synuclein levels [177]. The study will investigate cognitive and motor scales as well as changes in GCase reduction in lymphocytes and the pharmacokinetics of ambroxol. Another study on PD patients carrying a GBA mutation is currently ongoing in the USA and aims to investigate how the brain and motor behaviour changes in response to treatment (NCT03456687; Table 1). It is also important to note that clinical trials are also evaluating GLP-1 analogues in AD, such as a randomised, placebo-controlled phase II trial that is assessing the safety and efficacy of tiraglutide in 206 patients with early AD (NCT018430755). Another trial that aimed to evaluate exenatide in patients with AD or MCI (NCT01255163) was terminated due to insufficient recruitment.

5.2.3 GLP-1 Receptor Agonists

A phase II clinical trial is currently underway evaluating the GLP-1R agonist lixisenatide (NCT03439943; Table 1) as an add-on therapy for early-stage PD patients. However, the primary endpoint for this study is motor improvement with no specific interest in the cognitive aspects of the disease. In addition to this a phase II clinical trial with the GLP-1 analogue semaglutide and newly diagnosed PD patients is planned for early 2019 (NCT03659682; Table 1). In this trial cognitive assessment is also going to be examined among other parameters. Both of these drugs have demonstrated protective effects in preclinical studies [178, 179]. In addition to this the GLP-1 receptor agonist exenatide has been investigated in an open-label, randomised controlled trial of 45 patients with moderate PD [180]. In this study, exenatide was well-tolerated, although weight loss was a common concern. The single-blinded ratings of motor and cognitive performance suggested clinically relevant improvements in the treatment group compared with control. Patients who had previously been exposed to exenatide showed persistent advantage in motor and cognitive performance 1 year after study completion [181]. Following these encouraging results, a phase II randomised, double-blind, placebo-controlled study was conducted including 60 patients with PD who were allocated to exenatide or placebo for 48 weeks, followed by 12 weeks of washout period [182]. The study reported positive results on practically defined off-medication motor scores, which were sustained after the exposure period. However, no significant differences were observed in cognitive performance between exenatide and placebo. This may be due to the short observation period, combined with the mixed population including both early and more advanced PD patients. The observation period may not have been long enough to show significant changes in cognitive outcome [134]. Interestingly, in a post hoc analysis of the Exenatide-PD trial, the authors report improvement in cognition in the subgroups of patients with insulin resistance and those with obesity [183]. Another open-label study of exenatide in PD is currently ongoing in the USA and aims to investigate how the brain and motor behaviour changes in response to treatment (NCT03456687; Table 1). It is also important to note that clinical trials are also evaluating GLP-1 analogues in AD, such as a randomised, placebo-controlled phase II trial that is assessing the safety and efficacy of tiraglutide in 206 patients with early AD (NCT018430755). Another trial that aimed to evaluate exenatide in patients with AD or MCI (NCT01255163) was terminated due to insufficient recruitment.

6 Conclusions and Future Perspective

ChIs are being used for the treatment of PDD. However, there is a strong medical need for additional procognitive therapies. Several distinct pharmacological mechanisms are being targeted alone or together with ChIs to counteract MCI and PDD. T2DM appears to be associated with PD and neurodegenerative dementias, possibly through peripheral and cerebral insulin resistance that in turn results in altered autophagy, mitochondrial function, cell proliferation and increased inflammation. Drugs used in diabetes treatment have shown positive effects on neurodegenerative processes and on clinical outcome, regarding memory and cognition, and could, hopefully, be developed into novel therapies against PDD and related conditions. Since these drugs have primarily been developed for the treatment of T2DM, it is likely that a next generation of compounds with more BBB penetration may be better neuroprotective agents. The fact that the structure of GLP-1R has been solved will likely facilitate the development of non-peptidergic GLP-1 analogues.
compounds that may turn out to be favourable against neurodegeneration.

**Compliance with Ethical Standards**

**Conflict of interest** PS and PT are co-investigators on MOVES-PD and have been co-investigators in a clinical trial with IRL75 against dementia in Parkinson’s disease. PS has also received grants from Servier andonoraria from IRLAB, AbbVie and Shire. DA has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and serves as a paid consultant for H. Lundbeck, Eisai and Heptares. HG and IM have no conflicts of interest directly relevant to the content of this article.

**Funding** The work was supported by the Stockholm County Council (Grant number 20160372) and King’s College London. Per Svenningsson is a Wallenberg Clinical Scholar. Dag Aarsland is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation for their support. The open access fee was paid by Professor Svenningsson’s funding from the Karolinska Institutet.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.
2. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600–11.
3. Hong JY, Lee Y, Sunwoo MK, Sohn YH, Lee PH. Subjective cognitive complaints and objective cognitive impairment in Parkinson’s disease. J Clin Neurol. 2018;14(1):16–21.
4. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349–56.
5. Emre M, Aarsland D, Brown R, Burn DJ, Dyckjaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–707 (quiz 837).
6. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kolsch H, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414–22.
7. Erro R, Santangelo G, Barone P, Picillo M, Amboni M, Longo K, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? J Geriatr Psychiatry Neurol. 2014;27(4):276–81.
8. Roheger M, Kalbe E, Liepelt-Scarfone I. Progression of cognitive decline in Parkinson’s disease. J Parkinsons Dis. 2018;8(2):183–93.
9. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–9.
10. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697–707.
11. Aarsland D, Andersen K, Larsen JP, Lolik A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–92.
12. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.
13. Cukly G, Siraly E, Fodor Z, Horvath A, Salacz P, Hidasi Z, et al. The differentiation of amnestic type MCI from the non-amnestic types by structural MRI. Front Aging Neurosci. 2016;8:52.
14. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94.
15. Aarsland D, Creese B, Politis M, Chaudhuri KR, Fylythe DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–31.
16. Marras C, Armstrong MJ, Meaney CA, Fox S, Rothberg B, Regniold W, et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord. 2013;28(5):626–33.
17. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79–92.
18. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(PT 11):2958–69.
19. Association AP. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.
20. Jellinger KA, Korczyz AD. Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? BMC Med. 2018;16(1):34.
21. Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;15(374):26–31.
22. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurol. 2013;14(9):626–36.
23. Malek N, Lawton MA, Swallow DM, Grosset KA, Marrinan SL, Bajaj N, et al. Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson’s disease. Mov Disord. 2016;31(10):1518–26.
24. Lindqvist D, Hall S, Suroya Y, Nielsen HM, Janelidze S, Brundin L, et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013;33:183–9.
25. Bereczki E, Bogstedt A, Hoglund K, Tsitsi P, Brodin L, Ballard C, et al. Synaptic proteins in CSF relate to Parkinson’s disease stage markers. NPJ Parkinsons Dis. 2017;3:7.
26. O’Callaghan C, Lewis SJG. Cognition in Parkinson’s disease. Int Rev Neurobiol. 2017;133:557–83.
27. Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, et al. Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain. 2013;136(Pt 2):392–9.
28. Collins LM, Williams-Gray CH. The genetic basis of cognitive impairment and dementia in Parkinson’s disease. Front Psychiatrie. 2016;7:89.
29. Lleó A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, et al. Cerebrospinal fluid biomarkers in tri- als for Alzheimer and Parkinson diseases. Nat Rev Neurol. 2015;11(1):41–55.
30. Backstrom DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72(10):1175–82.

31. Hall S, Surova Y, Ohrfelt A, Blennow K, Zetterberg H, Hansson O. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease. Mov Disord. 2016;31(6):898–905.

32. Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):431–43.

33. Brooks DJ, Tambasco N. Imaging synucleinopathies. Mov Disord. 2016;31(6):814–29.

34. Lamskey JH, McCollan P, Schrag AE, Acosta-Cabronero J, Rees G, Morris HR, et al. Can neuroimaging predict dementia in Parkinson’s disease? Brain. 2018;141(9):2545–60.

35. Pereira JB, Svenningsson P, Weintraub D, Brønnick K, Lobecky A, Westman E, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology. 2014;82(22):2017–25.

36. Kunst J, Marecek R, Klobusiakova P, Balazova A, Anderkova J, Pae C-U, Lee C-U, Yang D, Chung Y, Suh T, et al. Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. Neurosci Res. 2005;52(3):211–9.

37. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Kadoya T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord. 2009;24(6):854–62.

38. Schindlleka KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson’s disease. Lancet Neurol. 2018;17(7):629–40.

39. Olde Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Berendse HW. Cognitive decline in Parkinson’s disease is associated with slowing of resting-state brain activity: a longitudinal study. Neurobiol Aging. 2013;34(2):408–18.

40. Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies. J Neural Transm (Vienna). 2018;125(4):615–50.

41. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014;29(5):634–50.

42. Barbeau A, Giguere R, Hardy J. Experience clinique avec le tolbutamide dans la maladie de Parkinson. Union Med Can. 1961:90:147–51.

43. Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology. 2012;78(19):1507–11.

44. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson’s disease in Denmark. Diabetes Care. 2011;34(5):1102–8

45. Xu Q, Park Y, Huang X, Hollebeek A, Blair A, Schatzkin A, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care. 2011;34(4):910–5.

46. Yue X, Li H, Yan H, Zhang P, Chang L, Li T. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine. 2016;95(18):e3549.

47. Bosco D, Plastino M, Cristiano D, Colica C, Ermic C, De Bartolo M, et al. Dementia is associated with insulin resistance in patients with Parkinson’s disease. J Neurol Sci. 2012;315(1–2):39–43.

48. Powers KM, Smith-Weller T, Franklin GM, Longstreth W Jr, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord. 2006;12(3):185–9.

49. Scigliano G, Musolico M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke. 2006;37(5):1184–8.

50. Lu L, Fu D-L, Li H-Q, Liu A-J, Li J-H, Zheng G-Q. Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PLoS One. 2014;9(1):e85781.

51. Moran LB, Graef MB. Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics. 2008;9(1):1–13.

52. Santiago JA, Potashkin JA. System-based approaches to decode the molecular links in Parkinson’s disease and diabetes. Neurobiol Dis. 2014;72:84–91.

53. Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson’s disease and diabetes. Diabetologia. 2013;56:209–12.

54. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(Suppl 1):S3–8.

55. Prince M, Ali GC, Guerchet M, Prina MA, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23.

56. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64–74.

57. Riederer P, Korczyn AD, Ali SS, Bajeneru O, Choi MS, Chopp M, et al. The diabetic brain and cognition. J Neural Transm (Vienna). 2017;124(11):1431–54.

58. Lynchinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007;64(4):570–5.

59. Knopman DS, Gottesman RF, Sharrett AR, Tapia AL, DavisThomas S, Windham BG, et al. Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: the Alzheimer’s Ercrosis Risk in Communities Study. Alzheimers Dement. 2018;14(11):1406–15.

60. Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ. Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol. 2015;14(3):329–40.

61. Palta P, Schneider AL, Biessels GJ, Touradji P, Hilt-Briggs F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc. 2014;20(3):278–91.

62. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and pre-diabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014;2(3):246–55.

63. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169–78.

Δ Adis
pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol. 2016;75(10):936–45.

107. Sharma SK, Chorell E, Steneberg P, Vernerson-Lindahl E, Edlund H, Wittung-Stafshede P. Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci Rep. 2015;5:12531.

108. Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm (Vienna). 2002;109(7–8):991–1002.

109. Mattila PM, Röyttä M, Lännberg P, Marjamäki P, Helenius H, Rinne JO. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol. 2001;102(2):160–6.

110. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord. 2011;26(14):2496–503.

111. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221(2):564–73.

112. Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today. 2016;21(3):802–18.

113. Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjöholm Å. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflammation. 2012;9(1):276.

114. Trapp S, Cork SC. PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. Am J Physiol Regul Integr Comp Physiol. 2015;309(8):R795–804.

115. Alvarez E, Martínez MD, Roncero I, Chown JA, García-Cuartero B, Gispert JD, et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem. 2005;92(4):798–806.

116. Merchenthaler I, Lane MPS. Distribution of pre-proglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1990;403(2):261–80.

117. Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease. Neuropharmacology. 2018;136(Pt B):260–70.

118. Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature. 2017;546(7654):248–53.

119. Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH. A new treatment strategy for Parkinson’s disease through the gut–brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant. 2018;27(6):1560–71.

120. Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, et al. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors—a nationwide case-control study. Mov Disord. 2010;25(2):218–20.

121. Athauda D, Foltynie T. Protective effects of the GLP receptor agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem. 2002;82(3):615–24.

122. Dehmer T, Heneka MT, Sastre M, Dichthans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with IkBa induction and block of NFkB and iNOS activation. J Neurochem. 2004;88(2):494–501.

123. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, et al. The GLP-1 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation. 2011;8(1):91.

124. Brauer R, Bhaskaran K, Chatuvedi N, Dexter DT, Smeth L, Douglas I. Glitazone treatment and incidence of Parkinson’s disease among people with diabetes: a retrospective cohort study. PLoS Med. 2015;12(7):e1001854.

125. Matteau E, Dupré N, Langlois M, Provencher P, Simard M. Clinical validity of the Mattis dementia rating scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol. 2012;25(2):100–6.

126. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FSZONE Investigators. Pioglitazone in early Parkinson disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14(8):795–803.

127. Lu CH, Yang CY, Li CY, Hsieh CY, Ou HT. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetesologia. 2018;61(3):562–73.

128. Kang MY, Oh TJ, Cho YM. Glucagon-like peptide-1 increases mitochondrial biogenesis and function in INS-1 rat insulinoma cells. Endocrinol Metab (Seoul). 2015;30(2):216–20.

129. Clark J, Reddy S, Zheng K, Betensky RA, Simon DK. Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson’s disease. BMC Med Genet. 2011;12(1):69.

130. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2(52):52ra73.

131. Mudo G, Mäkelä J, Di Liberto V, Tselykh TV, Olivieri M, Piepoli P, et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci. 2012;69(7):1153–65.

132. van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther. 2011;17(5):428–41.

133. O’Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKee I, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147–68.
177. Balestrino R, Schapira AHV. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist. 2018;24(5):540–59.

178. Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience. 2015;303:42–50.

179. Zhang L, Zhang L, Li L, Hölscher C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson’s disease mouse model. Neuropeptides. 2018;71:70–80.

180. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest. 2013;123(6):2730–6.

181. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis. 2014;4(3):337–44.

182. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–75.

183. Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Aviles-Olmos I, et al. Post hoc analysis of the Exenatide-PD trial—factors that predict response. Eur J Neurosci. 2018. https://doi.org/10.1111/ejn.14096 (Epub 2018 Aug 2).